Grail (NASDAQ:GRAL) Stock Price Down 6.7% – Here’s What Happened

Shares of Grail, Inc. (NASDAQ:GRAL) traded down 6.7% on Monday . The stock traded as low as $18.05 and last traded at $18.29. 165,412 shares traded hands during trading, a decline of 85% from the average session volume of 1,076,762 shares. The stock had previously closed at $19.60.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Wolfe Research assumed coverage on shares of Grail in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Morgan Stanley started coverage on Grail in a report on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price objective for the company. Finally, Guggenheim assumed coverage on Grail in a report on Thursday, October 17th. They issued a “neutral” rating on the stock.

Grail Trading Down 5.0 %

The stock’s fifty day moving average is $17.02.

Insider Transactions at Grail

In related news, CEO Robert P. Ragusa sold 123,454 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the sale, the chief executive officer now directly owns 612,661 shares in the company, valued at approximately $8,589,507.22. This trade represents a 16.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Aaron Freidin sold 30,452 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $14.02, for a total value of $426,937.04. Following the completion of the transaction, the chief financial officer now owns 268,277 shares of the company’s stock, valued at approximately $3,761,243.54. This represents a 10.19 % decrease in their position. The disclosure for this sale can be found here. Insiders acquired 58,829 shares of company stock valued at $757,298 over the last 90 days.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.